Literature DB >> 9062873

Clonal accumulation of V beta 5.1-positive cells in the liver of a patient with autoimmune cholangiopathy.

Y Shimizu1, K Higuchi, Y Kashii, M Miyamoto, T Tsukishiro, A Watanabe.   

Abstract

We describe a 43-year-old woman with clinical features compatible with autoimmune cholangiopathy recently reported by Ben Ari et al. She was negative for anti-mitochondrial antibody, positive for high titer anti-nuclear antibody with homogeneous pattern, high levels of serum immunoglobulin G and nearly normal levels of serum immunoglobulin M for more than five years. In the early stages of the disease, the elevations of serum transaminase, alkaline phosphatase and gamma-glutamyl transpeptidase were well controlled by the administration of ursodeoxycholic acid. After five years of follow-up, she showed the second exacerbation of liver function tests, which then rapidly improved by prednisone administration. To analyze the antigen diversity recognized by T-cells in the liver, T-cell receptor repertoire was examined by immuno-histochemistry. The liver biopsy obtained in the early stage showed clonal accumulation of V beta 5.1-positive cells in portal areas, which was found in patients neither with primary biliary cirrhosis nor autoimmune hepatitis. In conclusion, these data suggest that T-cell response in autoimmune cholangiopathy is different from those two autoimmune liver diseases, which may imply a distinct entity of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062873     DOI: 10.1111/j.1600-0676.1997.tb00771.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  2 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

2.  Similar T-cell oligoclonality in antimitochondrial antibody-positive and -negative primary biliary cirrhosis.

Authors:  M J Mayo; P E Lipsky; S N Miller; P Stastny; B Combes
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.